A Canadian gold project developer and a U.S. bank holding company both received analyst upgrades, one of which has an implied upside of nearly 50%.
| Company Name | Exchange | Ticker | Last Price | Market Cap | Recommendation | Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Sierra Metals Inc | TSX | SMT | 1.60 | 255.4 | Upgrade to hold from underweight | Timothy Stanish | EVA Dimensions | NA | NA |
| Athabasca Oil Corp | TSX | ATH | 2.40 | 964.9 | Upgrade to outperform from market perform | Chris Cox | Raymond James | 5.00 | 108.3% |
| Enbridge Income Fund Holdings Inc | TSX | ENF | 33.99 | 2,391.2 | Upgrade to sector outperform from sector perform | David Noseworthy | CIBC World Markets | 38.50 | 13.3% |
| ENTREC Corp | TSX | ENT | 0.63 | 67.8 | Downgrade to neutral from buy | Jason Zandberg | PI Financial Corp. | 0.70 | 11.1% |
EVA Dimensions upgraded Sierra Metals Inc (TSX: SMT), engaged in the business of mining precious and base metals from its Yauricocha mine in Peru and its Bolivar mine in Mexico, to hold from underweight. The rating company has not provided its target price for the company’s stock.
Athabasca Oil Corp (TSX: ATH), engaged in the exploration and development of unconventional oil resources, was upgraded by Raymond James to outperform from market perform with a price target of C$5.00, indicating an upside potential of 108.3% from current levels.
CIBC World Markets upgraded Enbridge Income Fund Holdings Inc (TSX: ENF), engaged in the business of making investments in a diversified portfolio of energy infrastructure assets in Canada, to sector outperform from sector perform by raising its price target to C$38.50 from C$32.75, indicating an upside of 13.3% from current levels.
PI Financial Corp. downgraded ENTREC Corp (TSX: ENT), engaged in the business of rigging and transporting overweight and oversized cargo, to neutral from buy by reducing its price target to C$0.70 from C$1.10, indicating an upside of 11.1% from current levels.
| Company Name | Exchange | Ticker | Last Price | Market Cap | Recommendation | Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| BOK Financial Corp | NASDAQ | BOKF | 62.58 | 4,339.1 | Upgrade to buy from neutral | Brett D Rabatin | Sterne Agee & Leach | 71.00 | 13.5% |
| Gentex Corp/MI | NASDAQ | GNTX | 37.70 | 5,518.9 | Upgrade to buy from hold | Brett D Hoselton | KeyBanc Capital Markets | 43.00 | 14.1% |
| Infinity Pharmaceuticals Inc | NASDAQ | INFI | 15.79 | 770.0 | Upgrade to outperform from neutral | Jason Kantor | Credit Suisse | 22.00 | 39.3% |
| CSI Compressco LP | NASDAQ | CCLP | 20.92 | 693.3 | Intiate with buy | Selman Akyol | Stifel | 23.50 | 12.3% |
| Kindred Biosciences Inc | NASDAQ | KIN | 6.10 | 120.3 | Downgrade to market perform from outperform | Seamus Fernandez | Leerink Partners LLC | 6.00 | -1.6% |
Sterne Agee & Leach upgraded BOK Financial Corp (NASDAQ: BOKF), engaged in the business of providing a range of deposit products, loans, and other financial services to businesses and consumers, to buy from neutral with a price target of $71.00, indicating an upside of 13.5% from current levels.
Gentex Corp/MI (NASDAQ: GNTX), engaged in designing, manufacturing and marketing products that use electro-optic technology, was upgraded by KeyBanc Capital Markets to buy from hold with a price target of $43.00, indicating an upside potential of 14.1% from current levels.
Credit Suisse upgraded Infinity Pharmaceuticals Inc (NASDAQ: INFI), engaged in the business of researching and developing cancer drugs, to outperform from neutral by raising its price target to $22.00 from $20.00, indicating an upside of 39.3% from current levels.
Stifel initiated coverage on CSI Compressco LP (NASDAQ: CCLP), engaged in providing wellhead compression-based production enhancement services, with a buy rating assigning a 12-month price target of $23.50, indicating an upside of 12.3% from current levels.
Kindred Biosciences Inc (NASDAQ: KIN), engaged in the business of developing effective medicines with a focus on saving and improving the lives of pets, was downgraded by Leerink Partners LLC to market perform from outperform by reducing its price target to $6.00 from $11.25, implying a downside potential of 1.6% from current levels.
